Home/Filings/4/0001209191-22-023845
4//SEC Filing

Hoelscher Paul W. 4

Accession 0001209191-22-023845

CIK 0001492426other

Filed

Apr 7, 8:00 PM ET

Accepted

Apr 8, 4:09 PM ET

Size

16.4 KB

Accession

0001209191-22-023845

Insider Transaction Report

Form 4
Period: 2022-04-06
Hoelscher Paul W.
EVP, Finance
Transactions
  • Exercise/Conversion

    Ordinary Shares

    2022-04-06$15.96/sh+30,275$483,18931,324 total
  • Sale

    Ordinary Shares

    2022-04-06$110.01/sh215,335$23,688,7881,049 total
  • Exercise/Conversion

    Ordinary Shares

    2022-04-06$22.14/sh+185,060$4,097,228216,384 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-04-0630,2750 total
    Exercise: $15.96Exp: 2024-06-26Ordinary Shares (30,275 underlying)
  • Sale

    Ordinary Shares

    2022-04-06$110.01/sh91,710$10,089,02666,673 total(indirect: By LLC)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-04-06185,06086,424 total
    Exercise: $22.14Exp: 2025-03-22Ordinary Shares (185,060 underlying)
Holdings
  • Ordinary Shares

    (indirect: By Trust)
    72,789
Footnotes (6)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021.
  • [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2021.
  • [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F5]These securities are held of record by Riviera Equity LLC. The Reporting Person and his spouse share voting power over the securities held by Riviera Equity LLC.
  • [F6]The option is fully vested and exercisable.

Issuer

Horizon Therapeutics Public Ltd Co

CIK 0001492426

Entity typeother

Related Parties

1
  • filerCIK 0001611468

Filing Metadata

Form type
4
Filed
Apr 7, 8:00 PM ET
Accepted
Apr 8, 4:09 PM ET
Size
16.4 KB